These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17210711)

  • 1. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
    Thanarajasingam U; Sanz L; Diaz R; Qiao J; Sanchez-Perez L; Kottke T; Thompson J; Chester J; Vile RG
    Cancer Res; 2007 Jan; 67(1):300-8. PubMed ID: 17210711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
    Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
    Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
    Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
    Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
    Yang SC; Batra RK; Hillinger S; Reckamp KL; Strieter RM; Dubinett SM; Sharma S
    Cancer Res; 2006 Mar; 66(6):3205-13. PubMed ID: 16540672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
    Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
    Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
    Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
    Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
    Jorritsma A; Bins AD; Schumacher TN; Haanen JB
    Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
    Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
    Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
    Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
    Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Lo AS; Ma Q; Liu DL; Junghans RP
    Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity.
    Turnquist HR; Lin X; Ashour AE; Hollingsworth MA; Singh RK; Talmadge JE; Solheim JC
    Int J Oncol; 2007 Mar; 30(3):631-9. PubMed ID: 17273764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression.
    Kjaergaard J; Shu S
    J Immunol; 1999 Jul; 163(2):751-9. PubMed ID: 10395667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
    Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
    Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells.
    Li J; Theofanous L; Stickel S; Bouton-Verville H; Burgin KE; Jakubchak S; Wagner TE; Wei Y
    Int J Oncol; 2007 Jul; 31(1):193-7. PubMed ID: 17549421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
    Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ tumor ablation creates an antigen source for the generation of antitumor immunity.
    den Brok MH; Sutmuller RP; van der Voort R; Bennink EJ; Figdor CG; Ruers TJ; Adema GJ
    Cancer Res; 2004 Jun; 64(11):4024-9. PubMed ID: 15173017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
    Kline J; Brown IE; Zha YY; Blank C; Strickler J; Wouters H; Zhang L; Gajewski TF
    Clin Cancer Res; 2008 May; 14(10):3156-67. PubMed ID: 18483384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.
    Rüttinger D; Li R; Poehlein CH; Haley D; Walker EB; Hu HM; Fox BA
    J Immunother; 2008 Jan; 31(1):43-51. PubMed ID: 18157011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.